Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies

• Published in: Frontiers in aging neuroscience Vol. 13; p. 712545
• Main Authors: Shi, Liu, Buckley, Noel J., Bos, Isabelle, Engelborghs, Sebastiaan, Sleegers, Kristel, Frisoni, Giovanni B., Wallin, Anders, Lléo, Alberto, Popp, Julius, Martinez-Lage, Pablo, Legido-Quigley, Cristina, Barkhof, Frederik, Zetterberg, Henrik, Visser, Pieter Jelle, Bertram, Lars, Lovestone, Simon, Nevado-Holgado, Alejo J.
• Format: Journal Article
• Language: English
• Published: Lausanne Frontiers Research Foundation 21.07.2021; Frontiers Media S.A
• Subjects: Aging; Alzheimer's disease; Alzheimer's disease (AD); Apolipoproteins; association; Biomarkers; blood; blood biomarkers; clinical-diagnosis; Cognitive ability; Cytotoxicity; Dementia; Dementia disorders; Diagnosis; Fibrinogen; Frontotemporal dementia; Geriatrics & Gerontology; insulin-resistance; Lifestyles; Lymphocytes T; Meta-analysis; national institute; Neurodegenerative diseases; neurofilament light; Neuroscience; Neurosciences; Neurosciences & Neurology; Neurovetenskaper; Pathology; phosphorylated tau 181; Plasma; Proteins; proteomic; α2-Macroglobulin; United States > US; San Francisco California; California
• ISSN: 1663-4365; 1663-4365
• DOI: 10.3389/fnagi.2021.712545

Background and Objective : Plasma biomarkers for the diagnosis and stratification of Alzheimer’s disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to AD pathology in multiple cohorts. The study aims to conduct a meta-analysis based on our own studies to systematically assess the diagnostic performance of our previously identified blood biomarkers. Methods : To do this, we included seven studies that our group has conducted during the last decade. These studies used either Luminex xMAP or ELISA to measure proteomic biomarkers. As proteins measured in these studies differed, we selected protein based on the criteria that it must be measured in at least four studies. We then examined biomarker performance using random-effect meta-analyses based on the mean difference between biomarker concentrations in AD and controls (CTL), AD and mild cognitive impairment (MCI), MCI, and CTL as well as MCI converted to dementia (MCIc) and non-converted (MCInc) individuals. Results : An overall of 2,879 subjects were retrieved for meta-analysis including 1,053 CTL, 895 MCI, 882 AD, and 49 frontotemporal dementia (FTD) patients. Six proteins were measured in at least four studies and were chosen for meta-analyses for AD diagnosis. Of them, three proteins had significant difference between AD and controls, among which alpha-2-macroglobulin (A2M) and ficolin-2 (FCN2) increased in AD while fibrinogen gamma chain (FGG) decreased in AD compared to CTL. Furthermore, FGG significantly increased in FTD compared to AD. None of the proteins passed the significance between AD and MCI, or MCI and CTL, or MCIc and MCInc, although complement component 4 (CC4) tended to increase in MCIc individuals compared to MCInc. Conclusions : The results suggest that A2M, FCN2, and FGG are promising biomarkers to discriminate AD patients from controls, which are worthy of further validation.